$AVR

L1 Capital trims Anteris Technologies Global Corp. (AVR) stake while still holding millions of indirect shares, CDIs and long-term warrants.

L1 Capital sold 7,800 shares of Anteris Technologies (AVR) at $8.83 each on 2026-08-28, reducing its indirect stake to 4,803,541 shares. It retains 5,359,470 CHESS Depository Interests and 1,333,334 warrants, both held indirectly. The warrants expire in 2030 with an exercise price of AUD 11.50.

Original reporting
Published Sep 1, 2026, 10:24 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 1:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

Traders may watch for follow-on selling or for whether the warrants’ exercise behavior changes, but the article provides no new company performance or guidance.

02

Market read

This is a modest insider trim with limited scale, more relevant for positioning and sentiment than for fundamentals.

03

What to watch

CHESS Depository Interests and warrants are indirect and exchangeable within 60 days, so the economic exposure may not change as much as the headline sale implies.

Relevance 4/10Novelty 4/10Timing: reported 2026-09-01, covering a sale dated 2026-08-28

Background

The piece summarizes an insider transaction disclosure tied to L1 Capital Pty Ltd, a 10% owner, reporting an indirect sale of common shares and retaining substantial indirect holdings plus warrants.

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd sold 7,800 Anteris shares at $8.83 on 2026-08-28, reducing indirect holdings to 4,803,541 shares.

Expected impact

Limited, likely sentiment-driven drift rather than a fundamental repricing.

Evidence & confidence

The article is a Form 4-style insider sale with modest share count ($69K) relative to remaining indirect holdings, and it does not disclose new operating or financial fundamentals.

Market effects

No clear sector read-through; this is a single-fund ownership change rather than an industry catalyst.

Minimal, since the disclosure is about a specific issuer’s insider position.

Low; no cross-border deal, regulation, or macro linkage is described.

Counterpoint

The sale may be routine portfolio rebalancing, and the continued large indirect stake plus long-term warrants suggests L1 is not exiting the thesis.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the insider sale disclosure; L1 Capital trimmed a small number of shares while retaining a large indirect position and warrants.

  • L1 Capital Pty Ltd

    Reported indirect sale of 7,800 shares at $8.83 and continued holdings via related funds, CDIs, and long-term warrants.

Related articles

$AVRMed

Anteris Advances DurAVR Toward Commercialization; PARADIGM Trial Expands U.S. Recruitment

Anteris Technologies Global Corp. (AVR) reported Q2 2026 results and said it secured U.S. Medicare reimbursement eligibility for PARADIGM Trial procedures. The company began U.S. recruitment, with first patients treated in May 2026, and said the trial is recruiting in the U.S., Denmark and the Netherlands. Net operating cash outflow was $20.8M; R&D expense was $23.4M.

$AVRMed

Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

Anteris Technologies (ASX:AVR, NASDAQ:AVR) said it advanced its pivotal PARADIGM Trial in the June quarter, enrolling and treating its first US patients after CMS Medicare reimbursement eligibility for qualifying procedures. Recruitment expanded to the US, Denmark and the Netherlands, with Canada and France receiving regulatory clearance. The trial targets about 1,000 patients. Net operating cash outflows were US$20.8m.

$AVRMedAI 8/10

Anteris Technologies Announces Results for the Second Quarter of 2026

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) reported Q2 2026 results for the quarter ended June 30, 2026. It said CMS granted Medicare reimbursement eligibility for the PARADIGM Trial, U.S. recruitment began with first patients treated in May 2026, and the trial expanded to multiple regions. Net operating cash outflows were $20.8M; R&D expenses were $23.4M.

$AVRLow

Anteris Technologies Global Corp. (AVR): Results of Operations and Financial Condition

Anteris Technologies Global Corp. (AVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Anteris Technologies Announces Results for the Second Quarter of 2026 MINNEAPOLIS, United States and BRISBANE, Australia August 12, 2026 (AEST) Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committe

$AVRMed

Anteris Technologies Global (NASDAQ:AVR) Shares Up 12.6% – Should You Buy?

Anteris Technologies Global (NASDAQ:AVR) shares rose 12.6% to $10.0750 on Thursday, after closing at $8.95; the stock traded between $9.71 and $10.0750. Volume was 176,960 shares, down 84% vs. average. Analysts cited mixed views: Barclays raised its target to $18 (overweight), while Wall Street Zen moved to hold; consensus target is $16. In its May 12 earnings, the company reported -$0.28 EPS vs -$0.27 expected on $0.49M revenue vs $0.77M.